Research Triangle Park

Syzygy Plasmonics Demonstrates Groundbreaking CO2-to-Fuel Solution with RTI International

Retrieved on:

火曜日, 5月 14, 2024

Hydrogen, Transport, Methane, Gasoline, Aviation, CH4, Research Triangle Park, Carbon, Climate change, RTI, Natural gas, CO2, FOAK, SAF, Carbon dioxide, Methanol, RTI International, Greenhouse, Fischer–Tropsch process

HOUSTON, May 14, 2024 /PRNewswire/ -- Syzygy Plasmonics announced today that it along with the nonprofit research institute RTI International have successfully demonstrated an all-electric CO2-to-Fuel production pathway at RTI's facility in Research Triangle Park, North Carolina, USA. The new technology can significantly decarbonize transportation by converting two potent greenhouse gases, carbon dioxide (CO2) and methane (CH4), into low-carbon-intensity fuels that can be used to lower the carbon footprint of fossil-based jet fuel, diesel, and gasoline. The pilot project was sponsored by Equinor Ventures and Sumitomo Corporation of Americas (SCOA).

Key Points:

HOUSTON, May 14, 2024 /PRNewswire/ -- Syzygy Plasmonics announced today that it along with the nonprofit research institute RTI International have successfully demonstrated an all-electric CO2-to-Fuel production pathway at RTI's facility in Research Triangle Park, North Carolina, USA.
A typical plant will consume nearly 200,000 tons of CO2 per year, the equivalent of taking 45,000 cars off the road.
"This project showcases our ability to fight climate change by converting harmful greenhouse gases into fuel," said Syzygy CEO Trevor Best.
"The results of this demonstration are encouraging and represent an important milestone in our collaboration with Syzygy," said Sameer Parvathikar, Ph.D., director of renewable energy and energy storage at RTI.

Solvias to Build Biologics and Cell & Gene Therapy Testing Center in Research Triangle Park

Retrieved on:

月曜日, 5月 6, 2024

Messenger, DNA, Research Triangle Park, Triangle Park (Quezon City), Research, Organization, AAV, CGT, NGS, Pharmaceutical industry

KAISERAUGST, Switzerland, May 6, 2024 /PRNewswire/ -- Solvias announced today that it is expanding its global network of laboratory testing centers with a new biotech site in Research Triangle Park, N.C. It is the company's latest investment to expand its analytical testing services supporting life science organizations with the growing number of cell and gene therapies (CGTs) and biologics in use and under development.

Key Points:

KAISERAUGST, Switzerland, May 6, 2024 /PRNewswire/ -- Solvias announced today that it is expanding its global network of laboratory testing centers with a new biotech site in Research Triangle Park, N.C.
It is the company's latest investment to expand its analytical testing services supporting life science organizations with the growing number of cell and gene therapies (CGTs) and biologics in use and under development.
It will offer critical cell-based potency assays, advanced Next-Gen Sequencing (NGS) capabilities, and related testing services supporting multiple biologic modalities.
From the outset, the new testing center will support characterization and release testing of CGT and other advanced therapies, including Adeno-Associated virus (AAV) gene therapies, mRNA therapies and antibody drug conjugates.

Solvias to Build Biologics and Cell & Gene Therapy Testing Center in Research Triangle Park

Retrieved on:

月曜日, 5月 6, 2024

Messenger, DNA, Research Triangle Park, Triangle Park (Quezon City), Research, Organization, AAV, CGT, NGS, Pharmaceutical industry

KAISERAUGST, Switzerland, May 6, 2024 /PRNewswire/ -- Solvias announced today that it is expanding its global network of laboratory testing centers with a new biotech site in Research Triangle Park, N.C. It is the company's latest investment to expand its analytical testing services supporting life science organizations with the growing number of cell and gene therapies (CGTs) and biologics in use and under development.

Key Points:

KAISERAUGST, Switzerland, May 6, 2024 /PRNewswire/ -- Solvias announced today that it is expanding its global network of laboratory testing centers with a new biotech site in Research Triangle Park, N.C.
It is the company's latest investment to expand its analytical testing services supporting life science organizations with the growing number of cell and gene therapies (CGTs) and biologics in use and under development.
It will offer critical cell-based potency assays, advanced Next-Gen Sequencing (NGS) capabilities, and related testing services supporting multiple biologic modalities.
From the outset, the new testing center will support characterization and release testing of CGT and other advanced therapies, including Adeno-Associated virus (AAV) gene therapies, mRNA therapies and antibody drug conjugates.

Civil Engineering Luminary Bill Derks Announces Retirement from McAdams

Retrieved on:

木曜日, 5月 2, 2024

RTP, HUB, Land development, Research Triangle Park, Kenyon College, Water resources, Transport, Engineering, Retirement, Pressure, Triangle, Growth, Management

RALEIGH, N.C., May 2, 2024 /PRNewswire/ -- McAdams, the Raleigh–based multidisciplinary design and engineering firm known for its expertise in civil / site design, land planning, landscape architecture, transportation, water resources, and geomatics, has announced the retirement of Bill Derks, Vice President of Land Development. Derks, who started with the firm in August 1996, has been instrumental in advancing some of the most significant development projects in the Raleigh-Durham area. His retirement on May 1, 2024, marks the culmination of a remarkable career at McAdams, capping a nearly 30-year tenure with the company.

Key Points:

Bill Derks, Esteemed Civil Engineer Since 1996, to Conclude Storied 27-Year Career at McAdams in May 2024
RALEIGH, N.C., May 2, 2024 /PRNewswire/ -- McAdams , the Raleigh–based multidisciplinary design and engineering firm known for its expertise in civil / site design, land planning, landscape architecture, transportation, water resources, and geomatics, has announced the retirement of Bill Derks, Vice President of Land Development.
His retirement on May 1, 2024, marks the culmination of a remarkable career at McAdams, capping a nearly 30-year tenure with the company.
Derks, who made a transition from business management and marketing to civil engineering, is revered for combining creative insight with analytical skills.
McAdams continues its commitment to maintaining the standards of quality and excellence that Bill Derks so perfectly embodied and helped establish throughout the team.

Immunovia streamlines lab operations with move to Research Triangle Park, North Carolina

Retrieved on:

月曜日, 4月 29, 2024

Survival, Research Triangle Park, Triangle Park (Quezon City), RTP, Pancreatic cancer

This work will be conducted at the lab in Research Triangle Park under the leadership and direction of Dr. Lisa Ford.

Key Points:

This work will be conducted at the lab in Research Triangle Park under the leadership and direction of Dr. Lisa Ford.
Moving its lab and U.S. headquarters to Research Triangle Park supports the strategy Immunovia announced in July 2023 to streamline operations and reduce costs.
The new space in Research Triangle Park (RTP) will be significantly smaller and less expensive than the company's existing lab in Marlborough, Massachusetts.
The lower cost of labor in Research Triangle Park should enable the company to staff the new lab at a lower cost.

Immunovia streamlines lab operations with move to Research Triangle Park, North Carolina

Retrieved on:

月曜日, 4月 29, 2024

Survival, Research Triangle Park, Triangle Park (Quezon City), RTP, Pancreatic cancer

This work will be conducted at the lab in Research Triangle Park under the leadership and direction of Dr. Lisa Ford.

Key Points:

This work will be conducted at the lab in Research Triangle Park under the leadership and direction of Dr. Lisa Ford.
Moving its lab and U.S. headquarters to Research Triangle Park supports the strategy Immunovia announced in July 2023 to streamline operations and reduce costs.
The new space in Research Triangle Park (RTP) will be significantly smaller and less expensive than the company's existing lab in Marlborough, Massachusetts.
The lower cost of labor in Research Triangle Park should enable the company to staff the new lab at a lower cost.

Grifols Celebrates 50 Years of Manufacturing Life-Changing Plasma-Derived Medicines for Patients at Flagship Site in Clayton, N.C.

Retrieved on:

木曜日, 4月 18, 2024

Fifty years ago, the site opened as Cutter Laboratories and produced modest quantities of a single medicine, albumin, distributed domestically.

Key Points:

Fifty years ago, the site opened as Cutter Laboratories and produced modest quantities of a single medicine, albumin, distributed domestically.
Its present plasma processing capacity of 12 million liters annually is more than half of the company’s current global capability.
Acquiring the site from Talecris Biotherapeutics in 2011 turned Grifols into a top-three plasma-sector powerhouse.
Innovations at Clayton are being replicated today at new Grifols manufacturing sites in Montreal, Canada, and Cairo, Egypt.

Imugene and Kincell Bio Announce Strategic Manufacturing and Process Development Partnership

Retrieved on:

火曜日, 4月 16, 2024

Sale, RTP, IMU, Research Triangle Park, ASX, Partnership, Patient, CGMP, Acquisition

As a result of the transfer, Imugene will recognize $32M USD in staff cost reductions, manufacturing efficiencies and overhead savings over the next three years

Key Points:

As a result of the transfer, Imugene will recognize $32M USD in staff cost reductions, manufacturing efficiencies and overhead savings over the next three years
With the transfer of the manufacturing facility and staff and the outsourcing of Azer-cel process development to Kincell, Imugene reduces staff by 50% and extends its cash runway to 2026
SYDNEY, Australia and GAINESVILLE, Fla., April 16, 2024 (GLOBE NEWSWIRE) -- Imugene, Ltd. (“Imugene”)(ASX: IMU) and Kincell Bio, LLC (“Kincell”), announce a strategic manufacturing and process development partnership, which includes the sale of Imugene’s North Carolina Current Good Manufacturing Practice (CGMP) manufacturing facility and the transfer of process and analytical development activities to Kincell.
Both parties have entered into a manufacturing supply agreement whereby Kincell will manufacture Imugene’s Azer-cel to support ongoing clinical trials.
Imugene will also transfer process and analytical development of Azer-cel to Kincell in order to support process and method optimization for commercial readiness.
We are confident that this strategic partnership with Kincell will enable Imugene to reach key upcoming data inflection points and extend the company’s cash runway to 2026.

Highwoods Announces Recent Disposition Activity

Retrieved on:

木曜日, 4月 4, 2024

GAAP, Research Triangle Park, HIW, Triangle Park (Quezon City), Sale, UNC Rex Healthcare, Bank

RALEIGH, N.C., April 04, 2024 (GLOBE NEWSWIRE) -- Highwoods Properties, Inc. (NYSE:HIW) has sold in a series of transactions non-core properties in Raleigh for combined gross proceeds of $79.4 million.

Key Points:

RALEIGH, N.C., April 04, 2024 (GLOBE NEWSWIRE) -- Highwoods Properties, Inc. (NYSE:HIW) has sold in a series of transactions non-core properties in Raleigh for combined gross proceeds of $79.4 million.
Gross proceeds from dispositions closed in the first quarter of 2024 totaled $16.9 million with the remainder closing early in the second quarter.
As part of the sale of one building, the Company provided $6.2 million in non-recourse first mortgage seller financing.
The note is scheduled to mature in February 2025, but can be prepaid without penalty at any time prior to maturity.

Merakris Therapeutics to Release Final Part 1 Data From Phase 2 Multicenter Investigational Drug Study for Dermacyte® Liquid

Retrieved on:

火曜日, 2月 20, 2024

Research Triangle Park, Triangle Park (Quezon City), FDA, Part, Vein, Leg, Skin, Conference, Veterans' affairs, Safety, Therapy, Patent, Part 1, Patient, PST, Clinical trial, Ulcer, Pharmaceutical industry

RESEARCH TRIANGLE PARK, N.C., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Merakris Therapeutics announced that it will present encouraging safety and efficacy data from the first of a two-part Phase 2 multi-center clinical study of its investigational wound care drug, Dermacyte® Amniotic Wound Care Liquid.

Key Points:

RESEARCH TRIANGLE PARK, N.C., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Merakris Therapeutics announced that it will present encouraging safety and efficacy data from the first of a two-part Phase 2 multi-center clinical study of its investigational wound care drug, Dermacyte® Amniotic Wound Care Liquid.
The study consented 12 patients who were assessed for eligibility to receive the investigational drug treatment.
Preliminary data indicate an 84% average reduction in ulcer surface area for the 9 patients completing the 12-week study.
These data are being analyzed by the Merakris scientific team and an independent data safety and monitoring committee and will inform the design of Part 2 of the multi-center clinical study.